Galimedix Therapeutics Commences Pivotal P-II Trial of GAL-101 Eye Drops for Treating Dry AMD
Shots:
- The pivotal P-II (eDREAM) study (funded by Théa Open Innovation) is to assess safety & efficacy of GAL-101 vs PBO for treating patients (n=110) with geographic atrophy (advanced form of dry AMD) across the US, EU & Israel
- The 1EP includes reduction in the rate of change of geographic atrophy lesion size while other assessments are changes in photoreceptor degeneration area & functional measures such as retinal sensitivity using a patient-tailored microperimetry grid
- GAL-101, a small molecule targeting misfolded Aβ monomers to prevent toxic aggregates, is being developed in oral and topical forms for dry AMD, glaucoma & Alzheimer’s disease. It has shown favorable safety & tolerability in P-I study
Ref: Galimedix Therapeutics | Image: Galimedix Therapeutics
Related News:- Ractigen Therapeutics Reports the First Patient Dosing with RAG-17 in P-I Study to Treat Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
